Article
Calreticulin variant stratified driver mutational status and prognosis in essential thrombocythemia.
American journal of hematology - 1 May 2016
Elala Yoseph C, Lasho Terra L, Gangat Naseema, Finke Christy, Barraco Daniela, Haider Mahnur, Abou Hussein Ahmed K, Hanson Curtis A, Ketterling Rhett P, Pardanani Animesh, Tefferi Ayalew
Abstract excerpt
About 85% of patients with essential thrombocythemia (ET) harbor one of three driver mutations: JAK2, calreticulin (CALR), and MPL; the remaining ( ∼15%) are wild type for all three mutations and are referred to as being "triple negative." Furthermore, CALR mutations in ET are structurally classified as type 1/type 1-like or type 2/type 2-like variants. The objective of the current study was to examine the impact...
Topics
Join the communities discussing this publication.